We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
-6.25%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$461M
AUM Growth
+$182M
(+65%)
Cap. Flow
-$27.6M
Cap. Flow
% of AUM
-6%
Top 10 Holdings %
Top 10 Hldgs %
74.85%
Holding
54
New
8
Increased
8
Reduced
20
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$6.76M |
| 2 |
FOLD
Amicus Therapeutics
FOLD
|
+$5.63M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$5.61M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$4.67M |
| 5 |
Axsome Therapeutics
AXSM
|
+$2.93M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$5.79M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$5.09M |
| 3 |
CMPS
Compass Pathways
CMPS
|
+$4.64M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
+$3.89M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$3.83M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 56.2% |
| 2 | Healthcare | 43.42% |
| 3 | Financials | 0.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Design Therapeutics
DSGN
$947M
| $3.23M | 0.7% |
200,000
+65,000
| +48% | +$996K |
|
|
27
Rocket Pharmaceuticals
RCKT
$424M
| $3.17M | 0.69% |
200,000
-225,000
| -53% | -$3.89M |
|
28
Xenon Pharmaceuticals
XENE
$5.79B
| $3.06M | 0.66% |
100,000
| – | – |
|
29
Relmada Therapeutics
RLMD
$473M
| $2.7M | 0.59% |
100,000
-100,000
| -50% | -$2.07M |
|
|
WHWK
30
Whitehawk Therapeutics
WHWK
$262M
| $2.55M | 0.55% |
150,000
-50,000
| -25% | -$958K |
|
31
Aclaris Therapeutics
ACRS
$908M
| $2.15M | 0.47% |
125,000
-200,000
| -62% | -$2.73M |
|
32
Tarsus Pharmaceuticals
TARS
$3.98B
| $2.02M | 0.44% |
120,000
-50,000
| -29% | -$928K |
|
|
NMTR
33
DELISTED
9 Meters Biopharma
NMTR
| $1.95M | 0.42% |
162,500
| – | – |
|
|
CRNX
34
DELISTED
Crinetics Pharmaceuticals
CRNX
| $1.87M | 0.4% |
85,000
-33,344
| -28% | -$675K |
|
|
STSA
35
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $1.8M | 0.39% |
473,562
-430,663
| -48% | -$1.94M |
|
|
CYPH
36
Cypherpunk Technologies Inc
CYPH
$261M
| $1.74M | 0.38% |
99,371
-35,629
| -26% | -$762K |
|
|
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.64M | 0.36% |
20,000
-10,000
| -33% | -$1.02M |
|
38
VistaGen Therapeutics
VTGN
$10.8M
| $1.63M | 0.35% |
43,838
-22,829
| -34% | -$995K |
|
39
Spyre Therapeutics
SYRE
$7.85B
| $1.58M | 0.34% |
+27,464
| New | +$2.31M |
|
|
PRDS
40
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $614K | 0.13% |
85,000
+35,000
| +70% | +$344K |
|
41
Larimar Therapeutics
LRMR
$398M
| $405K | 0.09% |
100,000
-125,000
| -56% | -$818K |
|
42
Pyxis Oncology
PYXS
$324M
| $303K | 0.07% |
75,000
-220,000
| -75% | -$1.61M |
|
43
CALL
Aldeyra Therapeutics
ALDX
$89.3M
| – | – |
-300,000
| Closed | -$1.2M |
|
|
44
Alnylam Pharmaceuticals
ALNY
$35.6B
| – | – |
-30,000
| Closed | -$5.09M |
|
45
Cabaletta Bio
CABA
$588M
| – | – |
-135,000
| Closed | -$512K |
|
|
CMPS
46
Compass Pathways
CMPS
$1.84B
| – | – |
-210,000
| Closed | -$4.64M |
|
47
GH Research
GHRS
$1.94B
| – | – |
-100,000
| Closed | -$2.33M |
|
48
Immunic
IMUX
$179M
| – | – |
-16,500
| Closed | -$1.58M |
|
49
CALL
Iovance Biotherapeutics
IOVA
$3.98B
| – | – |
-500,000
| Closed | -$9.54M |
|
50
Kura Oncology
KURA
$1.18B
| – | – |
-225,000
| Closed | -$3.15M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2022 Portfolio in Review
As of Q1 2022, Ghost Tree Capital held 54 positions worth $461M, up 65% from $279M the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Ghost Tree Capital withdrew a net $27.6M in Q1 2022, closing 12 positions and reducing 20 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $5.09M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 6.4% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Ghost Tree Capital opened a new position in Karuna Therapeutics, Inc. Common Stock worth $7.61M.
- Ghost Tree Capital's largest Q1 2022 buy was Karuna Therapeutics, Inc. Common Stock: 60,000 shares worth $7.61M.
- Ghost Tree Capital added most to Amicus Therapeutics in Q1 2022, an estimated $5.63M increase.
- Ghost Tree Capital's biggest Q1 2022 reduction was Ascendis Pharma A/S, cutting an estimated $5.79M.
- Ghost Tree Capital fully exited Alnylam Pharmaceuticals in Q1 2022, selling an estimated $5.09M.
- Ghost Tree Capital's ten largest holdings make up 75% of its $461M portfolio in Q1 2022.
- Ghost Tree Capital opened 8 new positions and closed 12 in Q1 2022.
- Ghost Tree Capital's portfolio value rose 65% quarter-over-quarter to $461M.
Based on Ghost Tree Capital's 13F filing for Q1 2022, filed 16 May 2022.